These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33914625)

  • 1. Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and/or chronic kidney disease.
    Campbell P; McKeveney P; Donegan K; Ataliotis C; Patton C; Mullan R
    Br J Hosp Med (Lond); 2021 Apr; 82(4):1-11. PubMed ID: 33914625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M
    Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: Analysis of French data from the PROKALE multinational European study].
    Rossignol P;
    Nephrol Ther; 2021 Oct; 17(6):422-427. PubMed ID: 33994135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patiromer: A Review in Hyperkalaemia.
    Blair HA
    Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.
    Mewton N; Girerd N; Boffa JJ; Courivaud C; Isnard R; Juillard L; Lamblin N; Legrand M; Logeart D; Mariat C; Meune E; Sabouret P; Sebbag L; Rossignol P
    Arch Cardiovasc Dis; 2020 Oct; 113(10):660-670. PubMed ID: 32660835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D; Banerjee D
    Curr Heart Fail Rep; 2022 Aug; 19(4):191-199. PubMed ID: 35704263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.